Investor Presentation • Nov 9, 2023
Investor Presentation
Open in ViewerOpens in native device viewer
ALEXANDER GEIS (CEO), FRANK LORENZ-DIETZ (CFO)
NOVEMBER 9, 2023










Strong performance across all metrics in Q3 and 9M 2023, despite OEM demand normalization in 1 EMEA. On track to deliver on targeted Haldex synergies and cross-selling targets for FY 2023

Increased profitability combined with strict NWC-management led to strong cash generation and 2 deleveraging close to FY 2024 leverage target

3 Double-digit ROCE constantly above WACC, creating notable shareholder value

Q3 2023 Highlights and regional performance

| Trading Review | up strongly by 37.4%, driven by Americas and APAC, robust aftermarket and Haldex Sales consolidation. Organic sales +13.2% |
|---|---|
| Development by Region | Strong double-digit organic sales growth in Americas and APAC, EMEA organically slightly down y-o-y due to demand normalization in Q3 |
| Aftermarket | of 68.3% to EUR 187.7 mn, driven by the consolidation of Significant aftermarket growth Haldex as well as prior OEM-business growth, increasing addressable aftermarket |
| Adj. EBIT margin | due to improvements in Americas and APAC, stable Increased adj. EBIT margin of 10.6% margin in EMEA. Avg. LTM margin of 9.3% in line with long-term target of 9 to 9.5% |
| Cash flow & leverage | Strong cash generation with operating free cash flow of EUR 71.1 mn led to a substantial from 2.6x (Dec'22) to 2.1x, close to FY 2024 target decrease in leverage |
| FY 2023 Outlook | Increased FY 2023 outlook is targeting sales of around EUR 2.1 bn and an adj. EBIT margin of around 9.5% |






(in EUR mn)
Group sales split (by region, by customer category)

8.3%
Q1 Q2 Q3 Q4

Group adj. EBIT by quarter (in EUR mn and % of sales) 6.4% 8.0% 9.1% 9.0% 9.1% 10.6% 23.5 43.4 32.1 36.7 32.3 50.8 58.6

191.4
200.5
Q1 Q2 Q3 Q4
230.9



9M 2023


EMEA adj. EBIT by quarter
(in EUR mn and % of sales)




9M 2023
Q1 Q2 Q3 Q4






APAC adj. EBIT by quarter
(in EUR mn and % of sales)



Financials 9M and Q3 2023

| in EUR mn | 9M 2023 | 9M 2022 | Change in % |
Q3 2023 | Q3 2022 | Change in % |
|---|---|---|---|---|---|---|
| EBIT | 124.9 | 75.7 | 65.1 | 52.6 1 |
27.0 | 95.3 |
| EBIT margin in % | 7.9 | 6.4 | - | 9.5 | 6.7 | – |
| Additional depreciation and amortization from PPA |
14.1 | 7.1 | 99.9 | 2 5.9 |
2.4 | >100 |
| Valuation effects from call and put options |
1.3 | 1.3 | -2.8 | 0.0 | 0.1 | -62.9 |
| Restructuring and transactions costs |
7.2 | 6.3 | 14.4 | 0.1 3 |
5.3 | -98.6 |
| Other adjustments | 5.3 | 2.0 | >100 | - | 2.0 | -100 |
| Adjusted EBIT | 152.8 | 92.3 | 65.6 | 58.6 | 36.7 | 59.8 |
| Adjusted EBIT margin in % | 9.6 | 7.8 | - | 10.6 | 9.1 | – |
Significantly lower one-off items as well as efficiency improvements led to significantly improved EBIT 1
Includes PPA from prior acquisitions and Haldex. Slightly above run-rate of ~ EUR 5 mn, due to FX-rate developments 2
Restructuring and transaction costs significantly reduced as initial post-merger integration for Haldex has been mostly completed. Upcoming topics will be legal entity consolidation as well as supply chain improvements at Haldex 3




Finance result includes FX-effects: Q3 2023 FX-effect was slightly negative against prior quarter, when a positive FX-effect was recorded. Run-rate for finance expenses expected to be ~ EUR -9 mn 1
Above usual tax rate of around 30% due to non-capitalized deferred tax assets on loss carryforwards and foreign tax rate differences at some subsidiaries. FY 2023 tax rate is expected to be around 35% 2



| Net working capital (in % of sales) | 11.9% | 14.4% | 14.8% | 15.5% | 14.8% | 15.7% | 17.4% | 15.9% | 12.0% | 15.6% | 15.4% | 14.5% | • • |
NWC ratio of SAF-HOLLAND was 14.5%, showing another sequential improvement due to ongoing strict NWC management Against Dec 2022 NWC increased due to the consolidation of Haldex, which had a significantly higher NWC ratio at around the 20%-mark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR mn | Dec 2020 |
Mar 2021 |
Jun 2021 |
Sep 2021 |
Dec 2021 |
Mar 2022 |
Jun 2022 |
Sep 2022 |
Dec 2022 |
Mar 2023 |
Jun 2023 |
Sep 2023 |
• | For better comparability, NWC of sales calculation, considers |
| Inventories | 126.4 | 155.8 | 176.0 | 195.3 | 194.0 | 211.9 | 237.0 | 237.9 | 202.2 | 308.4 | 305.7 | 308.3 | Haldex's contribution to sales | |
| Trade receivables |
95.3 | 130.0 | 148.9 | 147.2 | 136.3 | 176.1 | 184.6 | 187.0 | 144.7 | 283.0 | 286.4 | 253.2 | on a pro forma basis for the last twelve months, as Haldex's |
|
| Trade payables | -107.2 | -147.4 | -163.4 | -160.6 | -145.8 | -179.3 | -176.2 | -187.3 | -159.0 | -262.2 | -261.4 | -248.5 | contribution to NWC is also | |
| NWC | 114.6 | 138.4 | 161.5 | 181.9 | 184.4 | 208.7 | 245.5 | 237.6 | 188.0 | 329.2 | 330.7 | 313.0 | fully included since Q1 2023 | |
| Sales (LTM) | 959.5 | 961.7 | 1,091.4 | 1,175.6 | 1,246.6 | 1,330.7 | 1,411.7 | 1,497.5 | 1,565.1 | 2,112.8 | 2,143.2 | 2,165.1 |


Net cash flow from operating activities (EUR mn)


* Pre acquisitions / acquisition of Haldex shares

Return on capital employed (in %)

| EUR mn | Dec 2020 |
Mar 2021 |
Jun 2021 |
Sep 2021 |
Dec 2021 |
Mar 2022 |
Jun 2022 |
Sep 2022 |
Dec 2022 |
Mar 2023 |
Jun 2023 |
Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity | 300.5 | 325.2 | 334.8 | 353.7 | 371.1 | 390.5 | 431.1 | 468.5 | 441.4 | 449.8 | 433.4 | 468.8 |
| Financial liabilities | 324.1 | 332.4 | 323.7 | 318.5 | 322.2 | 318.9 | 369.9 | 614.5 | 715.7 | 663.3 | 683.8 | 663.6 |
| Lease liabilities | 43.6 | 42.7 | 41.6 | 41.7 | 41.1 | 40.4 | 40.9 | 39.9 | 38.4 | 62.7 | 68.0 | 67.4 |
| Pension provisions | 31.4 | 32.2 | 32.2 | 32.7 | 22.3 | 22.5 | 16.8 | 16.9 | 15.3 | 43.1 | 41.6 | 42.3 |
| Cash/cash equivalents |
-171.0 | -179.5 | -164.9 | -159.5 | -165.2 | -148.9 | -173.0 | -206.2 | -243.5 | -218.0 | -215.3 | -255.7 |
| Capital employed | 528.6 | 553.0 | 567.4 | 587.1 | 591.4 | 623.4 | 685.7 | 933.7 | 967.3 | 1,000.9 | 1,011.5 | 986.5 |
| Adjusted EBIT (LTM) |
58.8 | 62.3 | 82.1 | 91.5 | 93.1 | 94.7 | 101.8 | 114.1 | 124.6 | 165.0 | 172.6 | 180.3 |
* WACC calculation based on SAF-HOLLAND annual report FY 2021 and FY 2022


* Reported EBITDA (LTM) ** Excl. Haldex related debt Note: Net debt / EBITDA calculation from Dec 2022 onwards incl. Haldex related debt and pro-forma EBITDA (LTM) contribution

Outlook FY 2023 and key takeaways

| FY 2023e Trailer Market |
FY 2023e Trucks Market |
|
|---|---|---|
| EMEA | ~ -5% | ~ +10% |
| North America | ~ +8% | ~ +10% |
| Brazil | ~ -3% | ~ -20% |
| China | ~ +35% | ~ +20% |
| India | ~ +70% | ~ +14% |
| EMEA North America Brazil China India |
Exposure of Trailer OEM business* |
Exposure of Truck OEM business* |
* Indicative view showing the market exposure of the original equipment manufacturing (OEM) business of SAF-HOLLAND, based on the Groups Q3 2023 OEM sales
Note: Market forecasts are internal management assumptions based on truck-OEM communication, CLEAR int. (WEU and EEU, June and April 2023), ACT Research (North America, Sep 2023), ANFAVEA (Brazil, July 2022)

| Group FY 2023 Outlook as of 30 March 2023* |
Group FY 2023 Outlook as of 08 August 2023* |
Group FY 2023 Outlook as of 18 October 2023* |
|
|---|---|---|---|
| Sales | EUR 1,800 - 1,950 mn |
Slightly above EUR 2,000 mn |
Around EUR 2,100 mn |
| Adj. EBIT margin |
7.5% to 8.5% | Up to 9% | Around 9.5% |
| Capex ratio** | Up to 3% | Up to 3% | Up to 3% |
* Incl. Haldex contribution, consolidated as of February 21, 2023
** Incl. payments for investments in property, plant and equipment and intangible assets as well as capitalized R&D


1 Strong performance across all metrics in Q3 and 9M 2023, despite OEM demand normalization in EMEA

Increased profitability combined with strict NWC-management led to strong operating free cash 2 flow and deleveraging to 2.1x, close to FY 2024 target

3 Double-digit ROCE constantly above WACC, creating notable shareholder value

SAF-HOLLAND is targeting an adj. EBIT margin of around 9.5% in FY 2023, 4 significantly up from the 8.0% adj. EBIT margin achieved in FY 2022

Contact and additional information

| Issuer & contact | Financial calendar and road show activities | |
|---|---|---|
| SAF-HOLLAND SE Hauptstrasse 26 63856 Bessenbach |
November 23, 2023 | Hauck Aufhäuser Lampe Roadshow Lugano / Milan, virtual & IR-only |
| Fabian Giese Interim Head of Investor Relations, Corporate & ESG Communications Tel: +49 6095 301 – 904 |
December 04, 2023 | Kepler Cheuvreux Nordics Roadshow, virtual |
| December 06, 2023 | DZ Bank Roadshow, Frankfurt | |
| Alexander Pöschl Senior Manager Investor Relations, Corporate & ESG Communications Tel: +49 6095 301 – 117 |
December 20, 2023 | Berenberg Roadshow, Spain |
| January 11, 2024 | ODDO BHF Forum, Lyon | |
| Marleen Prutky Junior Manager Investor Relations Tel: +49 6095 301 – 592 |
January 17, 2024 | UniCredit / Kepler Chevreux German Corporate Conference, Frankfurt |
| March 14, 2024 | Publication of the FY 2023 Annual Report |
|
| Email: [email protected] | May 08, 2024 | Publication of the Quarterly Statement Q1 2024 |
| June 11, 2024 | Annual General Meeting | |
| August 08, 2024 | Publication of Half-Year Financial Report 2024 |
|
| November 07, 2024 | Publication of the Quarterly |

Statement Q3 2024
This presentation has been prepared by SAF-HOLLAND SE ("SAF-HOLLAND") and comprises written materials concerning SAF-HOLLAND. It is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. It contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation of SAF-HOLLAND or its business. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither SAF-HOLLAND nor any of the members of its management board or any of its officers, employees or advisors nor any other person shall have any responsibility or liability whatsoever (for negligence or otherwise) arising, directly or indirectly, from the use of this presentation, or its contents or otherwise in connection with this presentation.
This presentation contains certain statements related to our future business and financial performance and future events or developments involving SAF-HOLLAND and/or the industry in which SAF-HOLLAND operates that may constitute forward-looking statements. These statements may be identified by words such as "believes," "expects," "predicts," "intends," "projects," "plans," "estimates," "aims," "foresees," "anticipates," "targets," and similar expressions. Forward-looking statements are not historical facts, but solely opinions, views and forecasts which are based on current expectations and certain assumptions of SAF-HOLLAND's management or cited from third party sources which are uncertain and subject to risks. Actual events may differ significantly from the anticipated developments due to a number of factors, including without limitation, changes in general economic conditions, changes affecting the fair values of the assets held by SAF-HOLLAND and its subsidiaries, changes affecting interest rate levels, changes in competition levels, changes in laws and regulations, environmental damages, the potential impact of legal proceedings and actions and the Group's ability to achieve operational synergies from past or future acquisitions. Should any of these risks or uncertainties materialise or should underlying expectations not occur or assumptions prove to be incorrect, actual results, performance or achievements of SAF-HOLLAND may (negatively or positively) vary materially from those described, explicitly or implicitly, in the relevant forward-looking statement.
The information contained in this presentation, including any forward-looking statements expressed herein, speaks only as of the date hereof and reflects current legislation and the current business and financial affairs of the SAF-HOLLAND which are subject to change and audit. Neither the delivery of this presentation nor any further discussions of SAF-HOLLAND with any of the recipients thereof shall, under any circumstances, create any implication that there has been no change in the affairs of SAF-HOLLAND since such date. Consequently, SAF-HOLLAND neither accepts any responsibility for the future accuracy of the information contained in this presentation, including any forward-looking statements expressed herein, nor assumes any obligation, to update or revise this information to reflect subsequent events or developments which differ from those anticipated.
* This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. This presentation is for information purposes only and does neither constitute an offer to sell securities, nor any recommendation of, or solicitation of an offer to buy, any securities of SAF-HOLLAND in the United States, Germany or any other jurisdiction. In the United States, any securities may not be offered or sold absent registration or an exemption from registration under the U.S. Securities Act of 1933.
The information contained in this document has not been subject to any independent audit or review. Information derived from unaudited financial information should be read in conjunction with the relevant audited financial statements, including the notes thereto. Certain financial data included in the document consists of "non-IFRS financial measures". These non-IFRS financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with IFRS. You are cautioned not to place undue reliance on any non-IFRS financial measures and ratios included herein.

Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.